Internal Medicine, Rheumatology · La Mesilla, NM
NPI
1992844989
Since 2007
Specialty
Internal Medicine, Rheumatology
Code 207RR0500X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
1770 Tierra de Mesilla
La Mesilla, NM, 88046
Phone (575) 526-9189
Groups this clinician bills Medicare through
Medicare paid, 2024
$1.3M
107,549 services
Medicare patients, 2024
274
Average age 73
Drug cost, 2024
$5.7M
2,064 prescriptions
Company payments, 2025
$7,483
From 12 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Adrian A Michael was code J0717 (injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)), 60,800 times for 19 patients. In total Adrian A Michael billed 107,549 services in 31 codes, and Medicare paid $1.3M.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2014-05-07.
| Code | Setting | Services | Patients | Paid per service | Medicare paid |
|---|
| J0717 Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 60,800 | 19 | $3.52 | $214K |
| J0129 Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 14,825 | 25 | $33.72 | $500K |
| J0897 Injection, denosumab, 1 mg | Office | 1,800 | 17 | $20.61 | $37K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 406 | 233 | $11.91 | $4,834 |
| 96372 Injection Administration | Office | 320 | 33 | $10.60 | $3,392 |
| 99215 Office E&M - Established | Office | 298 | 176 | $124.24 | $37K |
| 96365 Intravenous Infusion, Hydration | Office | 278 | 38 | $45.09 | $13K |
| 99214 Office E&M - Established | Office | 206 | 141 | $83.44 | $17K |
| 96415 Chemotherapy Administration | Office | 81 | 11 | $20.18 | $1,635 |
| 96413 Chemotherapy Administration | Office | 65 | 15 | $91.85 | $5,970 |
| 99205 Office E&M - New | Office | 25 | 25 | $149.58 | $3,739 |
| 99213 Office E&M - Established | Office | 19 | 19 | $61.23 | $1,163 |
By year: 2022 $1.0M for 55,545 services; 2023 $1.1M for 78,770 services; 2024 $1.3M for 107,549 services.
Medicare prescription drug claims, 2024
In 2024, the drug Adrian A Michael prescribed most often to Medicare patients was Hydroxychloroquine Sulfate, with 340 prescriptions and refills. In total Adrian A Michael wrote 2,064 Medicare prescriptions that cost $5.7M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Hydroxychloroquine Sulfate Generic | 340 | 908 | 103 | $17K |
| Methotrexate Methotrexate Sodium | 199 | 533 | 82 | $6,293 |
| Enbrel Sureclick Etanercept | 136 | 151 | 17 | $1.2M |
| Leflunomide Generic | 127 | 355 | 51 | $9,592 |
| Prednisone Generic | 117 | 184 | 57 | $1,207 |
| Celecoxib Generic | 112 | 314 | 43 | $6,583 |
| Humira(Cf) Pen Adalimumab | 98 | 105 | 14 | $1.2M |
| Cimzia (2 Pack) Certolizumab Pegol | 88 | 97 | Under 11 | $611K |
| Meloxicam Generic | 83 | 235 | 40 | $780 |
| Alendronate Sodium Generic | 62 | 154 | 18 | $521 |
| Folic Acid Generic | 61 | 189 | 28 | $580 |
| Allopurinol Generic | 56 | 160 | 15 | $886 |
| Orencia Clickject Abatacept | 38 | 38 | Under 11 | $220K |
| Simponi Golimumab | 35 | 45 | Under 11 | $295K |
| Diclofenac Sodium Generic | 34 | 44 | 19 | $3,181 |
Brand drugs: - claims; generic drugs: 1,360 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Adrian A Michael $7,483 ($7,483 in general payments such as food, travel and fees) from 12 companies. The largest payer was Abbvie Inc. with $6,427.
| Company | Payments | Amount |
|---|---|---|
| Abbvie Inc. ABBV | 27 | $6,427 |
| UCB, Inc. UCB.BR | 13 | $246 |
| Amgen Inc. AMGN | 16 | $233 |
| Novartis Pharmaceuticals Corporation NVS | 8 | $227 |
| AstraZeneca Pharmaceuticals LP AZN | 9 | $175 |
| GlaxoSmithKline, LLC. GSK | 3 | $58.06 |
| Pfizer Inc. PFE | 1 | $29.5 |
| Mallinckrodt Hospital Products Inc. | 1 | $19.88 |
| Aurinia Pharma U.S., Inc. AUPH | 1 | $18.91 |
| Radius Health, Inc. | 1 | $18.4 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.